CRT 25 - Safety and effectiveness outcomes of the Agent drug-coated balloon (DCB) for the treatment of in-stent restenosis show a major reduction in target lesion failure, including cardiac death, myocardial infarction and target lesion revascularization, compared to balloon angioplasty. The Agent DCB also caused a significant reduction in all target lesion events in comparison with the control arm.

Dr Jeffrey Moses (Columbia University Medical Center, New York, US) sits down to outline the two-year outcomes from AGENT IDE (NCT04647253; Boston Scientific Corporation), a prospective, 2:1 randomized, multi-centre trail. AGENT IDE investigated the Agent paclitaxel-coated balloon catheter compared to balloon angioplasty in patients with in-stent restenosis and high-grade lesions.

Interview Questions:
1. What gaps in current treatment approaches for in-stent restenosis did this study aim to address?
2. What was the study design and patient population?
3. What were the key findings?
4. What safety outcomes were measured, and were there any unexpected safety signals?
5. How might these findings influence clinical decision-making for interventional cardiologists treating in-stent restenosis?
6. What further research is required, and what are the next steps?

Recorded remotely from New York, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.